PARP inhibitor olaparib increases the oncolytic activity of dl922‐947 in in vitro and in vivo model of anaplastic thyroid carcinoma

PARP inhibitors are mostly effective as anticancer drugs in association with DNA damaging agents. We have previously shown that the oncolytic adenovirus dl922‐947 induces extensive DNA damage, therefore we hypothesized a synergistic antitumoral effect of the PARP inhibitor olaparib in association wi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Mol Oncol
Huvudupphovsmän: Passaro, Carmela, Volpe, Massimiliano, Botta, Ginevra, Scamardella, Eloise, Perruolo, Giuseppe, Gillespie, David, Libertini, Silvana, Portella, Giuseppe
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2014
Ämnen:
Research Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528680/
https://ncbi.nlm.nih.gov/pubmed/25139258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.07.022
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk